“Bioprinting’s importance for pharmaceutical analysis is paramount now, not only for potential Covid-19 treatments but also for testing treatments for cancer and other diseases,” states a recent article from the New York Times extolling groundbreaking developments in the 3D printing industry.

Read how researchers are using revolutionary 3D bioink printers such as BRINTER®’s bioprinting platform to test drug efficacy against bacteria and infectious diseases and move towards the creation of skin and full-size organs.